Skip to content
Menu

BridgeBio Pharma, Inc. BBIO

Full chart Compare
Set alert

Price alert · BBIO

All alert types
78.18 USD +0.17 (+0.22%)

Regular-session close

78.93 +0.75 +0.96%

After hours · Nov 19, 6:49 PM ET

77.94 Day range 79.88
62.50 52-week range 93.42
YTD
+2.21%
1 year
+19.29%

5D +1.56 (+2.00%)

7678FriMonTueWedThu79.56
Market cap
15.23B
Revenue (ttm)
945.54M
Profit margin
-59.84%
EPS (ttm)
-3.03
Shares out
194.80M
Forward P/E
-286.02
YTD return
+2.21%
1-year return
+19.29%
50-day average
70.11
200-day average
72.69
Volume
2.16M
Avg volume
2.67M
Open
78.41
Previous close
78.01
Day's range
77.94 – 79.88
52-week range
62.50 – 93.42
Beta
0.94
Analysts
Strong Buy
Price target
107.00 (+36.9%)
Earnings date
Feb 23, 2027

Key statistics

Enterprise value
17.99B
Price / sales
16.11
Revenue growth
192.60%
Free cash flow
-287.13M
Total cash
1.54B
Total debt
3.38B
Short % of float
11.95%

Fundamental scorecard

6 of 25 checks passed on BBIO’s reported financials

ValueGrowthProfitabilityHealthDividend

6of 25 checks passed

  • Value 1 of 5
  • Growth 3 of 5
  • Profitability 1 of 5
  • Financial health 1 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
BBIO Revenue — quarterly 353.17M
BBIO Net income — quarterly -56.71M
BBIO EPS — quarterly -0.42

Earnings

BBIO recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Feb 23, 2027Dec 30, 2026-0.59———
Oct 29, 2026Sep 30, 2026-0.54225-0.42+0.12+22.54%
Aug 10, 2026Jun 30, 2026-0.57558-0.78-0.20-35.52%
May 7, 2026Mar 31, 2026-0.67877-0.84-0.16-23.75%
Feb 24, 2026Dec 31, 2025-0.71343-1.00-0.29-40.17%
Oct 29, 2025Sep 30, 2025-0.88-0.95-0.07-7.95%

Upgrades / downgrades

BBIO analyst upgrades and downgrades
DateFirmActionFromTo
Nov 13, 2026Morgan StanleymainOverweightOverweight
Nov 2, 2026Canaccord GenuitymainBuyBuy
Oct 30, 2026TD CowenmainBuyBuy
Oct 30, 2026Morgan StanleymainOverweightOverweight
Oct 21, 2026Morgan StanleymainOverweightOverweight
Oct 19, 2026CitigroupmainNeutralNeutral

About BridgeBio Pharma, Inc.

BridgeBio Pharma, Inc., a biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or transthyretin-mediated amyloidosis (ATTR-CM); Fosdenopterin, an intravenous formulation of synthetic cyclic pyranopterin monophosphate for the treatment of molybdenum cofactor deficiency under the NULIBRY brand name; and low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 clinical stage or the treatment of children with achondroplasia and hypochondroplasia. It also develops Encaleret, an oral small molecule, negative allosteric modulator of the calcium sensing receptor, which is in phase 3 clinical study for the treatment of Autosomal Dominant Hypocalcemia Type 1(ADH1) and Chronic Hypoparathyroidism (CHP); BBP-418, an investigational, orally administered, and small molecule therapy that is in phase 3 clinical study for the treatment of LGMD2I; and BBP-812, an investigational adeno-associated virus (AAV) gene therapy for Canavan disease. In addition, the company engages in developing products for mendelian, oncology, and gene therapy diseases. It has license and collaboration agreements with the Bayer Consumer Care AG, Alexion Pharma International Operations Limited Company, Leland Stanford Junior University, and Novartis International Pharmaceutical Ltd. BridgeBio Pharma, Inc. was founded in 2015 and is headquartered in Palo Alto, California.

Sector
Healthcare
Industry
Biotechnology
Country
United States

News

Your note

Sign in to keep a note on BBIO — it syncs with the Stock Master app.

Insider holders

BBIO insider holders
InsiderRelationLatest transactionDateShares held
APULI MARICELOfficerSaleOct 29, 2026120,687
HOMCY CHARLES JDirectorStock Award(Grant)Jun 21, 2026919,876
KKR GENETIC DISORDER L.P.Beneficial Owner of more than 10% of a Class of SecuritySaleMay 11, 20250
KUMAR NEILChief Executive OfficerSaleSep 16, 20260
MCCORMICK FRANK P. PH.D.DirectorStock Award(Grant)Jun 21, 2026767,244
MOMTAZEE JAMES CDirectorStock Award(Grant)Jun 21, 202699,070

Institution ownership

BBIO institution ownership
Holder% heldSharesValueReported
Janus Henderson Group Ltd.7.47%14,555,0101.14BSep 29, 2026
Farallon Capital Management LLC7.31%14,247,0001.11BSep 29, 2026
Blackrock Inc.5.33%10,388,689812.19MSep 29, 2026
Viking Global Investors, L.P.5.03%9,792,219765.56MSep 29, 2026
Wellington Management Group, LLP4.86%9,458,992739.50MSep 29, 2026
Kohlberg Kravis Roberts & Co. L.P.4.24%8,260,971645.84MSep 29, 2026

Fund ownership

BBIO fund ownership
Holder% heldSharesValueReported
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund2.87%5,600,403437.84MJun 29, 2026
VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund2.07%4,039,952315.84MJun 29, 2026
VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund1.62%3,162,851247.27MJul 30, 2026
VANGUARD INDEX FUNDS-Vanguard Small-Cap Growth Index Fund1.20%2,330,329182.19MJun 29, 2026
VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund1.01%1,974,544154.37MJun 29, 2026
SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF1.00%1,942,329151.85MSep 29, 2026